These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27285067)

  • 21. Synthesis and structure-activity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides.
    Siwek A; Stączek P; Stefańska J
    Eur J Med Chem; 2011 Nov; 46(11):5717-26. PubMed ID: 21978836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity.
    Baumann S; Herrmann J; Raju R; Steinmetz H; Mohr KI; Hüttel S; Harmrolfs K; Stadler M; Müller R
    Angew Chem Int Ed Engl; 2014 Dec; 53(52):14605-9. PubMed ID: 25510965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
    Kathiravan MK; Kale AN; Nilewar S
    Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases.
    Barbosa LC; Garrido SS; Garcia A; Delfino DB; Santos Ldo N; Marchetto R
    Eur J Med Chem; 2012 Aug; 54():591-6. PubMed ID: 22749642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Meinke PT; Olsen DB; Lagrutta A; Wei C; Liao Y; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Yajima M; Shibue T; Shibata T; Ohata K; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3636-43. PubMed ID: 26141771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites.
    Lamba S; Roy A
    Drug Discov Today; 2023 Jun; 28(6):103574. PubMed ID: 37003515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leveraging structural information for the discovery of new drugs: computational methods.
    Nguyen TB; Wong SE; Lightstone FC
    Methods Mol Biol; 2012; 841():209-34. PubMed ID: 22222454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.
    Perola E; Stamos D; Grillot AL; Ronkin S; Wang T; LeTiran A; Tang Q; Deininger DD; Liao Y; Tian SK; Drumm JE; Nicolau DP; Tessier PR; Mani N; Grossman TH; Charifson PS
    Bioorg Med Chem Lett; 2014 May; 24(9):2177-81. PubMed ID: 24685546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase.
    Singh SB
    Bioorg Med Chem; 2016 Dec; 24(24):6291-6297. PubMed ID: 27143131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
    Sandhaus S; Chapagain PP; Tse-Dinh YC
    Sci Rep; 2018 Jan; 8(1):1437. PubMed ID: 29362471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria.
    Surivet JP; Zumbrunn C; Bruyère T; Bur D; Kohl C; Locher HH; Seiler P; Ertel EA; Hess P; Enderlin-Paput M; Enderlin-Paput S; Gauvin JC; Mirre A; Hubschwerlen C; Ritz D; Rueedi G
    J Med Chem; 2017 May; 60(9):3776-3794. PubMed ID: 28406300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Gill C; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takeuchi T; Shibue T; Ohata K; Takano H; Ban S; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2473-8. PubMed ID: 25978963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An improved assay for the detection of alterations in bacterial DNA supercoiling in vivo.
    Abu Mraheil M; Heisig A; Heisig P
    Pharmazie; 2013 Jul; 68(7):541-8. PubMed ID: 23923635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New inhibitors of bacterial topoisomerase GyrA/ParC subunits.
    Black MT; Coleman K
    Curr Opin Investig Drugs; 2009 Aug; 10(8):804-10. PubMed ID: 19649925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
    Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
    You F; Gao C
    Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA topoisomerases as molecular targets for anticancer drugs.
    Buzun K; Bielawska A; Bielawski K; Gornowicz A
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1781-1799. PubMed ID: 32975138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
    Reck F; Alm R; Brassil P; Newman J; Dejonge B; Eyermann CJ; Breault G; Breen J; Comita-Prevoir J; Cronin M; Davis H; Ehmann D; Galullo V; Geng B; Grebe T; Morningstar M; Walker P; Hayter B; Fisher S
    J Med Chem; 2011 Nov; 54(22):7834-47. PubMed ID: 21999508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA Topoisomerases of Leishmania Parasites; Druggable Targets for Drug Discovery.
    Reguera RM; Elmahallawy EK; García-Estrada C; Carbajo-Andrés R; Balaña-Fouce R
    Curr Med Chem; 2019; 26(32):5900-5923. PubMed ID: 29773051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.